Stake on transfer: evolution of a regulatory framework for the development of the pharmaceutical industry


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Drug technology transfer is one of the ways to provide the country's population with affordable and effective drugs. The development of the pharmaceutical industry and government initiatives aimed at modernizing healthcare make Russia attractive to international pharmaceutical business, which in turn allows the Russian pharmaceutical industry to obtain modern world-class technologies and equipment, high-tech jobs, and production management methods and enables partners to have a guaranteed sales market. However, despite the importance and priority of drug technology transfer, foreign manufacturers face a variety of economic and legal problems when making strategic decisions on technology transfer. The development of high-tech production of medicines is associated with the technology transfer process. The above process arises from the transition from one stage of the drug life cycle to the next one. The important feature characterizing the transfer process is the regulation of the transfer of knowledge and technologies, which should ensure the stable safety of a drug and its efficacy, and the reproducibility of quality control methods, by taking into account the results of industrial production. The above aspects of drug circulation are laid down at the stage of development. The specificity of the pharmaceutical industry lies in the need to develop technologies in the context of market globalization and intense competition in drug development, production, and sales. In this connection, the export opportunities of states come to the fore, the important part of which is the convenience of registering and launching modern, effective, safe and competitive drugs in terms of price on the international market.

全文:

受限制的访问

作者简介

Alexander Rudko

OOO «NOVAMEDIKA INNOTECH»

Email: rudkoa@inbox.ru
Director General

Dmitry Konikov

Saint Petersburg State Chemopharmaceutical University

Email: kdl68@mail.ru
Master's student, f

Kirill Sidorov

Saint Petersburg State Chemopharmaceutical University

Researcher of the Department of scientific research

Julia Ilyinova

Saint Petersburg State Chemopharmaceutical University

Email: yulia.ilynova@pharminnotech.com
Vice-rector for academic affairs

参考

  1. Правительство РФ, Постановление от 15 апреля 2014 г. №305 «Об утверждении государственной программы Российской Федерации «Развитие фармацевтической и медицинской промышленности».
  2. Наркевич И.А., Умаров С.З. Технологическая модернизация процессов лекарственного обеспечения в лечебно-профилактических учреждениях. Менеджер здравоохранения. 2013; 1: 44-9.
  3. Информационный портал «Новости GMP». Режим доступа: https://gmpnews.ru (дата обращения: 10.12.2019).
  4. Постановление Правительства РФ от 30 ноября 2015 гг. №1289 «Об установлении ограничений доступа иностранных лекарственных препаратов при государственных закупках».
  5. Приказ Министерства финансов от 4 июня 2018 г. №126н «Об условиях допуска товаров, происходящих из иностранного государства или группы иностранных государств, для целей осуществления закупок для обеспечения государственных и муниципальных нужд».
  6. WHO guidelines on Transfer of Technology in pharmaceutical manufacturing №961. 2011; (7): 286-309.
  7. ISPE «Good Practice Guide: Technology Transfer. Third Edition»
  8. Государственная фармакопея XIV издания. Том I. [Электронное издание]. Режим доступа: http://resource.rucml. ru/feml/pharmacopia/14_1/HTML/207/index.html (дата обращения: 10.12.2019).

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2020